CG Oncology (CGON) Retained Earnings (2023 - 2026)
CG Oncology posted quarterly Retained Earnings of -$439.2 million for Q1 2026, down 73.98% year-on-year from -$1.7 billion in Q1 2025, and down 15.89% on a QoQ basis from -$379.0 million in Q4 2025.
CG Oncology (CGON) has 4 years of Retained Earnings data on file, last reported at -$439.2 million in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 73.98% year-over-year to -$439.2 million; the trailing twelve-month figure through Mar 2026 stood at -$439.2 million (down 73.98% YoY), and the FY2025 full-year result was -$379.0 million, down 73.86% from the prior year.
- Retained Earnings for Q1 2026 stood at -$439.2 million, down from -$379.0 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$129.9 million in Q4 2023 and bottomed at -$439.2 million in Q1 2026.
- The 4-year median for Retained Earnings is -$235.2 million (2024), against an average of -$254.9 million.
- The widest annual swing landed in 2024, when Retained Earnings sank 67.75%; it then sank 81.36% in 2025.
- A 4-year view of Retained Earnings shows it stood at -$129.9 million in 2023, then plunged by 67.75% to -$218.0 million in 2024, then plunged by 73.86% to -$379.0 million in 2025, then fell by 15.89% to -$439.2 million in 2026.
- The last three Retained Earnings figures came in at -$439.2 million (Q1 2026), -$379.0 million (Q4 2025), and -$337.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | CG Oncology | 5.01 Bn | 5.01 Bn | -1.88 Mn | -439.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -439.18 Mn |
| Dec 31, 2025 | -378.98 Mn |
| Sep 30, 2025 | -337.70 Mn |
| Jun 30, 2025 | -293.86 Mn |
| Mar 31, 2025 | -252.43 Mn |
| Dec 31, 2024 | -217.98 Mn |
| Sep 30, 2024 | -186.20 Mn |
| Jun 30, 2024 | -165.80 Mn |
| Mar 31, 2024 | -146.87 Mn |
| Dec 31, 2023 | -129.94 Mn |